Resource Center
Resource Center >> Webinars
Download

SRU BIND – A Plate-based, Label-free Detection Platform for Cell-based and In Vitro Biochemical Applications

SRU presents its BIND® technology, a robust, plate-based, universal assay system that enables label-free detection of biomolecular interactions. The system is comprised of the BIND Reader and 96-, 384- or 1536-well microplate BIND Biosensors. The BIND system takes advantage of a novel optical effect that generates very sensitive measurements of changes in binding or adherence in the proximity of the biosensor surface. This presentation will discuss BIND’s use as a drug profiling and screening tool for live cell-based and in vitro biochemical applications.

>> View a recording of the webinar
>> Download a PDF of the presentation
Download

Filling in the Gaps of Early Drug Discovery with High-Throughput Label-Free Biosensors: Hope, Hype or Truth?

Julio Jose Martin, Manager Screening and Compound Profiling, GlaxoSmithKline

About the speaker
J. Julio Martin is currently working at the Molecular Discovery Research automation facility of GlaxoSmithKline in Tres Cantos (Spain). This R&D centre is devoted to the industrialisation of HTS operations. As manager of one of the groups, he is responsible for ultra-HTS campaigns from screen development to dose-response and preliminary SAR. He has been engaged in the development and implementation of new statistical tools and assay technologies for the improvement of HTS efficiency. He holds a PhD degree in Biochemistry from University of Madrid. Prior to his current position, he was working at the R&D Department of Glaxo in Madrid from 1990 until 2001. As Head of Biochemistry, he managed programmes for discovery of new antimicrobial leads, contributing to the elucidation of the mechanism of action of Sordarins, a novel class of antifungals.

Abstract
Plate-based label-free optical biosensors constitute a versatile platform enabling a broad range of applications: from biomolecular complexes to phenotypic alterations in native cells, from the interaction between small organic molecules and proteins to the redistribution of intracellular mass upon receptor activation, from screening of compound libraries to mechanistic pharmacology of leads, from agonist trafficking to receptor panning. Drug discovery paradigm is shifting from the pursuit of magic bullets hitting single targets to the exploitation of systems biology complexity and the understanding of drug pharmacology in a native texture. Optical label-free constitutes a valuable seamless link between the direct screening of any target for small compound binders and the biological complexity of native cells. Several efforts across early drug discovery can benefit by it: fragment-based screening, novel hit identification strategies, hit (in)validation, orthogonal readout, hit-to-lead, lead optimization, etc. Rather than replacing, it can enable, complement or simplify some of the existing methodologies. The amenability to high-throughput in a cost-effective manner can make complex assays accessible. Nevertheless, it is not all gold that glitters, and there exist technological and economic challenges and uncertainties that can be addressed but might also jeopardize the vast adoption of this incipient methodology by the community. In the upcoming years we will see whether the hope was just hype or the promise is delivered.

>> View a recording of the webinar